ABSTRACT
Background Radiologic evidence of air trapping (AT) on expiratory computed tomography (CT) scans is associated with early pulmonary dysfunction in patients with cystic fibrosis (CF). However, standard techniques for quantitative assessment of AT are highly variable, resulting in limited efficacy for monitoring disease progression.
Objective To investigate the effectiveness of a convolutional neural network (CNN) model for quantifying and monitoring AT, and to compare it with other quantitative AT measures obtained from threshold-based techniques.
Materials and Methods Paired volumetric whole lung inspiratory and expiratory CT scans were obtained at four time points (0, 3, 12 and 24 months) on 36 subjects with mild CF lung disease. A densely connected CNN (DN) was trained using AT segmentation maps generated from a personalized threshold-based method (PTM). Quantitative AT (QAT) values, presented as the relative volume of AT over the lungs, from the DN approach were compared to QAT values from the PTM method. Radiographic assessment, spirometric measures, and clinical scores were correlated to the DN QAT values using a linear mixed effects model.
Results QAT values from the DN were found to increase from 8.65% ± 1.38% to 21.38% ± 1.82%, respectively, over a two-year period. Comparison of CNN model results to intensity-based measures demonstrated a systematic drop in the Dice coefficient over time (decreased from 0.86 ± 0.03 to 0.45 ± 0.04). The trends observed in DN QAT values were consistent with clinical scores for AT, bronchiectasis, and mucus plugging. In addition, the DN approach was found to be less susceptible to variations in expiratory deflation levels than the threshold-based approach.
Conclusion The CNN model effectively delineated AT on expiratory CT scans, which provides an automated and objective approach for assessing and monitoring AT in CF patients.
Competing Interest Statement
We have the following interests. This study was partly supported by Novartis Institutes for Biomedical Research, Cambridge, MA, USA, from which Dr. Terry E. Robinson received a research grant. There are no patents, products in development or marketed products to declare.
Funding Statement
This study was supported by the following grants funded to the people indicated by their side: 1. NHLBI/NIH R01HL139690: Dr. Craig J. Galban 2. NHLBI/NIH R44HL140890: Dr. Craig J. Galban, Dr. Charles R. Hatt 3. NHLBI/NIH R01HL150023: Dr. Craig J. Galban, Dr. Meilan K. Han, Dr. Charles R. Hatt 4. CF Foundation Grant LAMA20AB0: Dr. Craig J. Galban, Dr. Vibha Lama 5. Novartis Institute of Biomedical Research: Dr. Terry E. Robinson The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards at Stanford University Medical Center and Nationwide Childrens Hospital, and full informed consent was obtained from the parents or guardians of the children, and the childs assent was also obtained. Name / affiliations of all ethics committees / Institutional Review Boards that ruled the ethics of the study: Michael D. Amylon, M.D. Chair, Panel on Medical Human Subjects, Stanford University IRB Panel Number: 5136 (Panel: 7) Protocol ID: 6218 Ethical approval was given. See below. Certification of Human Subjects Approvals. Title of Protocol: A Two Year Study to Assess the Natural History of Progressive CF Lung Disease Utilizing Controlled Volumetric Lung CT Imaging, Pulmonary Function Measurements, and Clinical Scores in Children with Mild CF Lung Disease.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the paper and its Supporting Information files.
